{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:02:20Z","timestamp":1781539340182,"version":"3.54.5"},"reference-count":22,"publisher":"Impact Journals, LLC","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,9,10]]},"DOI":"10.18632\/oncotarget.27103","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T04:21:48Z","timestamp":1568089308000},"page":"5403-5411","source":"Crossref","is-referenced-by-count":18,"title":["Predictive value of interim FDG-PET\/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP"],"prefix":"10.18632","volume":"10","author":[{"given":"Kazuhiro","family":"Kitajima","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine and PET Center, Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazuko","family":"Tokugawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Internal Medicine, Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Uegahara Hospital, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Schmitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Lister","year":"2007","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Patrick","year":"2016","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Rapezzi","year":"2018","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Meignan","year":"2005","journal-title":"Blood"},{"key":"7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/annonc\/mdn629","article-title":"High incidence of false-positive PET scans in patients with aggressive non-Hodgkin\u2019s lymphoma treated with rituximab-containing regimens","volume":"20","author":"Lossos","year":"2009","journal-title":"Ann Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","article-title":"Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning","volume":"15","author":"Swinnen","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy","volume":"50","author":"Meignan","year":"2009","journal-title":"J Nucl Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Meikle","year":"2010","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","article-title":"Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab","volume":"30","author":"Haioun","year":"2012","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Morschhauser","year":"2011","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation","volume":"52","author":"Bartlett","year":"2011","journal-title":"J Nucl Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Puccini","year":"2012","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Haioun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Samarin","year":"2015","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.crad.2015.11.019","article-title":"Prognostic value of negative interim 2-[\u00b9F]-fluoro-2-deoxy-d-glucose PET\/CT in diffuse large B-cell lymphoma","volume":"71","author":"An","year":"2016","journal-title":"Clin Radiol"},{"key":"18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2967\/jnumed.118.210807","article-title":"Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET\/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials","volume":"59","author":"Zijlstra","year":"2018","journal-title":"J Nucl Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"H\u00fcttmann A1 PETAL Trial Investigators. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial","volume":"36","author":"D\u00fcrig","year":"2018","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00259-018-4198-6","article-title":"Prognostic analysis of interim 18F-FDG PET\/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy","volume":"46","author":"Li","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"21","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis","volume":"85","author":"Kwee","year":"2016","journal-title":"Eur J Radiol"},{"key":"22","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"O\u2019Doherty","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T14:50:36Z","timestamp":1591455036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":22,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2019,9,10]]}},"alternative-id":["27103","31534626"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27103","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}